《千金要方》“开心散”对血管性痴呆患者血浆ICAM-1影响研究  

The Effects of Kaixinsan in Qianjinyaofang for Ready Reference on Plasma ICAM-1 in Patients with Vascular Dementia

作　　者：刘彦廷 蔡忠明 陈应柱 

机构地区：[1]江苏省扬州市中医院脑病科,江苏扬州225000 [2]苏北人民医院神经内科,江苏扬州225000

出　　处：《中医药临床杂志》2015年第10期1423-1425,共3页Clinical Journal of Traditional Chinese Medicine

基　　金：江苏省中医药局科技项目支助课题(LZ13191)

摘　　要：目的:探讨《千金要方》中"开心散"对血管性痴呆(VD)的治疗效果及机制。方法:200例VD患者随机分为2组,治疗组和对照组各100例,2组在针对基础病进行对症治疗的同时,对照组给予安理申5mg每晚临睡前口服,治疗组给予中药"开心散"治疗,1个月为1个疗程。采用MMSE评估患者的智能状况,采用酶联免疫吸附测定法(ELISA)检测VD患者血浆ICAM-1值。结果:2组患者治疗后智能状况及血浆ICAM-1值均较同组治疗前有所改善;治疗组MMSE积分明显高于对照组,有统计学差异;但2组治疗后血浆ICAM-1值之间无明显差异。结论:《千金要方》中"开心散"对VD患者有明显的治疗作用,对血浆ICAM-1的影响是其可能的作用机制。Objective：To explore the therapeutic effects and mechanism of action of Kaixinsan in Qianjinyaofang for Ready Reference for the treatment of VD. Methods： 200 VD patients were randomized into either the treatment group or control group, 100 in each group. Both groups received symptomatic treatment for the underlying disease, to which Kaixinsan, a traditional Chinese medicine, was added in the treatment group, and Aricept 5mg per oral was added every night before bed in the control group. MMSE was used to evaluate patients metal state, and enzyme-linked immunosorbent assay （ELISA） was used to detect the plasma ICAM-1 level in VD patients. Resuhs： Treatment in both groups resulted in improvements in mental state and plasma ICAM-1 level as compared to prior to treatment （P〈0.05）; while the posttreatment MMSE score was significantly higher in the treatment group than in the control group （P〈0.05）, there was no significant difference between the two groups in post-treatment plasma ICAM-1 level （P〉0.05）. Conclusion： Kaixinsan in Qianjinyaofang for Ready Reference produced significant therapeutic effects for VD patients, with the effect on plasma ICAM-I being the potential mechanism of action.

关 键 词：《千金要方》 开心散 血管性痴呆 ICAM-1 

分 类 号：R259[医药卫生—中西医结合]